These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
495 related articles for article (PubMed ID: 21045142)
1. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Kapuria V; Peterson LF; Fang D; Bornmann WG; Talpaz M; Donato NJ Cancer Res; 2010 Nov; 70(22):9265-76. PubMed ID: 21045142 [TBL] [Abstract][Full Text] [Related]
2. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422 [TBL] [Abstract][Full Text] [Related]
3. Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response. Perry JW; Ahmed M; Chang KO; Donato NJ; Showalter HD; Wobus CE PLoS Pathog; 2012; 8(7):e1002783. PubMed ID: 22792064 [TBL] [Abstract][Full Text] [Related]
5. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas. Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Karpel-Massler G; Banu MA; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD Oncotarget; 2016 Mar; 7(11):12791-805. PubMed ID: 26872380 [TBL] [Abstract][Full Text] [Related]
7. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase. Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502 [TBL] [Abstract][Full Text] [Related]
9. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Peterson LF; Sun H; Liu Y; Potu H; Kandarpa M; Ermann M; Courtney SM; Young M; Showalter HD; Sun D; Jakubowiak A; Malek SN; Talpaz M; Donato NJ Blood; 2015 Jun; 125(23):3588-97. PubMed ID: 25814533 [TBL] [Abstract][Full Text] [Related]
10. A small molecule deubiquitinase inhibitor increases localization of inducible nitric oxide synthase to the macrophage phagosome and enhances bacterial killing. Burkholder KM; Perry JW; Wobus CE; Donato NJ; Showalter HD; Kapuria V; O'Riordan MX Infect Immun; 2011 Dec; 79(12):4850-7. PubMed ID: 21911458 [TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis. Liu Y; Xu X; Lin P; He Y; Zhang Y; Cao B; Zhang Z; Sethi G; Liu J; Zhou X; Mao X J Biol Chem; 2019 Mar; 294(12):4572-4582. PubMed ID: 30718275 [TBL] [Abstract][Full Text] [Related]
13. Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. Zhao C; Chen X; Yang C; Zang D; Lan X; Liao S; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; Dou QP; Wang X; Liu J Oncotarget; 2017 Feb; 8(8):13942-13956. PubMed ID: 28086217 [TBL] [Abstract][Full Text] [Related]
14. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969 [TBL] [Abstract][Full Text] [Related]
15. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925 [TBL] [Abstract][Full Text] [Related]
16. USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells. Lu Q; Zhang FL; Lu DY; Shao ZM; Li DQ Cancer Med; 2019 Nov; 8(15):6730-6740. PubMed ID: 31512408 [TBL] [Abstract][Full Text] [Related]
17. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies. Didier R; Mallavialle A; Ben Jouira R; Domdom MA; Tichet M; Auberger P; Luciano F; Ohanna M; Tartare-Deckert S; Deckert M Mol Cancer Ther; 2018 Jul; 17(7):1416-1429. PubMed ID: 29703842 [TBL] [Abstract][Full Text] [Related]
18. A ubiquitinome analysis to study the functional roles of the proteasome associated deubiquitinating enzymes USP14 and UCH37. van der Wal L; Bezstarosti K; Demmers JAA J Proteomics; 2022 Jun; 262():104592. PubMed ID: 35489684 [TBL] [Abstract][Full Text] [Related]